Azenta, Inc. (Nasdaq: AZTA), today announced the appointment of three new independent directors to its Board.
William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta’s ongoing initiative to ensure a best-in-class Board that has resulted in significant Board refreshment in the past two years.
Also, as part of the Board’s process, Quentin Koffey, Founder, Managing Partner and Chief Investment Officer of Politan Capital Management (“Politan”), which owns 9.4% of Azenta common stock, joins as a Director. Azenta and Politan have entered into a cooperation agreement that provides for the addition of Mr. Koffey to the Board, among other matters.
“The addition of these new independent directors further demonstrates Azenta’s commitment to ensuring we have a well-rounded Board with the right mix of skillsets and experience. We are excited to welcome William, Quentin and Alan,” said Frank E. Casal, Chairman of Azenta’s Board of Directors. “Their diverse set of skills complement our Board’s existing strengths. William’s operational expertise leading companies to profitable growth, Quentin’s experience enhancing capital allocation, and Alan’s track record of fostering life sciences innovation will be invaluable as we continue our focus on expanding margins and enhancing profitability to further drive long-term shareholder value creation.”
“I am honored to join Azenta’s Board,” said Mr. Cornog. “Since becoming a standalone business, Azenta has built a strong foundation with a clear runway for growth, and the Company is poised to generate meaningful shareholder value.”
“As long-term investors in Azenta, we are confident the Company has significant opportunities ahead to unlock and drive shareholder value,” said Mr. Koffey. “We appreciate our constructive engagement with Azenta, and I look forward to collaborating with the Board and management to best position the Company for the future.”
“In the dynamic life sciences industry, Azenta has proven its commitment to innovate for customers,” said Mr. Malus. “I am thrilled to join the Board and help advance Azenta’s mission to enable impactful scientific breakthroughs faster.”
Azenta’s Board has established a new Value Creation Committee to, in consultation with senior management of the Company, assist and advise the Board in its responsibilities relating to long-term value creation, including growth and cost initiatives and high-level capital deployment. The initial members of the Value Creation Committee are William Cornog, Quentin Koffey, Martin Madaus, Alan Malus, and John Marotta and the committee will be chaired by William Cornog.
Azenta also reaffirms its full year 2024 financial guidance provided on August 6th, 2024.
As part of the cooperation agreement and to facilitate collaboration, Azenta and Politan have agreed to customary standstill, voting and other provisions. The cooperation agreement will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.
About William L. Cornog
William L. Cornog is the former head of KKR Capstone, the portfolio operations team of KKR & Co. In addition to leading Capstone, Mr. Cornog chaired KKR’s portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Currently, Mr. Cornog is a board member at Brightview Holdings Inc. (NYSE: BV) and LiveWire (NYSE: LVWR). He is Chairman of the Audit Committee and the Conflicts Committee of LiveWire.
About Quentin Koffey
Quentin Koffey is Founder, Managing Partner and Chief Investment Officer of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017.
About Alan J. Malus
Alan J. Malus is the former Corporate Executive Vice President of Thermo Fisher. Prior to that, Mr. Malus served as President, Laboratory Products and Services at Thermo Fisher. He has held various leadership positions and senior executive positions in finance, marketing, commercial development and operations since joining Thermo Fisher in 1998. Previously, Mr. Malus served as an independent director at PHC Holdings Corp., a global healthcare company, headquartered in Japan.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.
